Introduction
Pemitinib 13.5 mg is identified on this website as a product containing pemigatinib, an oral targeted anticancer medicine that inhibits FGFR1, FGFR2 and FGFR3.
Pemigatinib is used in selected cancer treatment settings involving specific genetic abnormalities. Although it provides a targeted approach to cancer treatment, it can cause adverse reactions that require medical supervision.
Understanding the potential risks before and during treatment is important for patients, caregivers and healthcare professionals.
This page explains important safety considerations associated with pemigatinib, including blood phosphate changes, eye problems, drug interactions, pregnancy-related risks and regular monitoring.
1. Hyperphosphatemia
Hyperphosphatemia is an increase in the amount of phosphate in the blood.
It is an important adverse reaction associated with pemigatinib because FGFR inhibition can affect normal phosphate regulation.
When phosphate levels become elevated, calcium-phosphate deposits may develop in soft tissues. This can lead to complications that require medical management.
Patients taking pemigatinib should have their blood phosphate levels monitored according to the prescribing instructions.
Management may include:
- Monitoring phosphate levels.
- Dietary phosphate management.
- Phosphate-lowering medicines.
- Temporary treatment interruption.
- Dose reduction when clinically appropriate.
Patients should follow their healthcare professional’s dietary and treatment recommendations.
2. Ocular Toxicity and Vision Changes
Pemigatinib can cause ocular adverse reactions, including retinal pigment epithelial detachment (RPED).
This condition affects the retina and can interfere with normal vision.
Eye monitoring is important throughout treatment.
Under U.S. reference-product prescribing information, patients should receive an eye examination, including optical coherence tomography (OCT), before starting treatment.
Follow-up examinations are recommended every two months during the first six months and every three months afterward while treatment continues. Additional examinations may be required if symptoms develop.
Patients should promptly report:
- Blurred vision.
- New visual floaters.
- Flashes of light.
- Changes in color perception.
- Other new or worsening visual disturbances.
Patients should not wait for their next routine eye examination if they experience visual symptoms.
3. Nail Toxicity
Pemigatinib may cause changes in the fingernails and toenails.
Possible problems include nail separation, discoloration, brittleness, tenderness and changes in nail growth.
These effects may interfere with daily activities if they become severe.
Patients should keep their nails clean and avoid unnecessary trauma to the affected areas.
Persistent pain, swelling, redness or signs of infection should be discussed with a healthcare professional.
4. Skin Reactions
Skin-related adverse reactions may occur during pemigatinib treatment.
These can include dryness, irritation, rash and changes in skin texture.
Patients should report persistent or worsening skin problems.
Healthcare professionals may recommend appropriate skin care or other treatment depending on the nature and severity of the reaction.
Severe skin reactions require prompt medical evaluation.
5. Gastrointestinal Effects
Pemigatinib may cause gastrointestinal adverse reactions such as:
- Diarrhea.
- Nausea.
- Vomiting.
- Constipation.
- Abdominal discomfort.
- Stomatitis.
- Reduced appetite.
Diarrhea can become clinically significant if it is persistent or severe.
Patients should contact their healthcare professional if diarrhea causes dehydration, significant weakness or difficulty maintaining normal fluid intake.
Severe abdominal pain, persistent vomiting or other serious gastrointestinal symptoms should also be assessed promptly.
6. Fatigue and Reduced Appetite
Fatigue and decreased appetite may occur during treatment.
Some patients may experience reduced energy, difficulty completing usual activities or changes in their eating habits.
Maintaining adequate nutrition and discussing persistent fatigue with the treating specialist can help identify possible causes.
Fatigue should not automatically be attributed to the medicine because cancer itself and other medical conditions can also contribute to tiredness.
7. Drug Interactions
Pemigatinib can interact with medicines that affect drug-metabolizing enzymes, particularly CYP3A.
Strong or moderate CYP3A inducers may decrease pemigatinib exposure.
Strong or moderate CYP3A inhibitors may increase pemigatinib exposure.
These changes can affect treatment effectiveness and safety.
Patients should provide their healthcare professionals with a complete list of:
- Prescription medicines.
- Nonprescription medicines.
- Vitamins.
- Herbal preparations.
- Dietary supplements.
- Other cancer treatments.
Patients should not start or discontinue another medicine without discussing potential interactions with their healthcare professional.
8. Grapefruit and Food-Related Precautions
Grapefruit and grapefruit juice may affect the metabolism of certain medicines.
Patients taking pemigatinib should discuss grapefruit consumption with their healthcare professional and follow the instructions in the applicable product information.
Pemigatinib may generally be taken with or without food under U.S. reference-product instructions.
The actual product’s administration instructions should always be followed.
9. Pregnancy and Embryo-Fetal Risk
Pemigatinib may cause fetal harm.
Pregnancy status and reproductive plans should be discussed with the treating specialist before treatment begins.
Under U.S. reference-product labeling, females of reproductive potential should use effective contraception during treatment and for one week after the final dose.
The potential risks to male patients and their partners should also be discussed with a healthcare professional.
Patients who become pregnant during treatment should contact their treating specialist promptly.
10. Breastfeeding Considerations
Patients who are breastfeeding or planning to breastfeed should discuss treatment with their healthcare professional.
The potential for serious adverse reactions in a breastfed infant must be considered.
The decision about breastfeeding during treatment should be made using the applicable prescribing information and individual clinical circumstances.
11. Kidney and Liver Function
Kidney and liver function may influence pemigatinib dosing and treatment management.
Patients with severe renal or hepatic impairment may require a reduced starting dose under U.S. reference-product prescribing information.
Healthcare professionals should assess relevant organ function and determine whether treatment modification is necessary.
Patients should report any new medical diagnosis involving the kidneys or liver during treatment.
12. Important Monitoring Requirements
Monitoring helps identify adverse reactions and supports appropriate treatment decisions.
Depending on the patient’s circumstances, monitoring may include:
| Monitoring area | Purpose |
|---|---|
| Blood phosphate | Identify hyperphosphatemia |
| Eye examination | Detect ocular toxicity |
| OCT | Assess retinal changes |
| Kidney function | Evaluate renal health |
| Liver function | Assess hepatic health |
| Skin and nails | Identify dermatological reactions |
| Gastrointestinal symptoms | Evaluate treatment tolerance |
| Medication review | Identify potential interactions |
The treating specialist determines the appropriate monitoring frequency.
13. Who Should Be Evaluated Carefully Before Treatment?
A healthcare professional should assess patients with relevant medical conditions or circumstances before prescribing pemigatinib.
These may include:
- Significant kidney impairment.
- Severe liver impairment.
- Existing eye disorders.
- Pregnancy or plans for pregnancy.
- Breastfeeding.
- Use of medicines that affect CYP3A enzymes.
- Previous serious reactions to treatment.
The absence of a formal contraindication in U.S. reference-product labeling does not mean that pemigatinib is suitable for every patient.
14. When to Seek Medical Attention
Patients should promptly contact their healthcare professional if they experience new or worsening symptoms.
Urgent assessment may be necessary for:
- Sudden visual changes.
- Severe or persistent diarrhea.
- Significant dehydration.
- Severe allergic symptoms.
- Serious or rapidly worsening skin reactions.
- Other symptoms considered urgent by the treating team.
For a medical emergency, seek immediate medical care.
15. Importance of Following Prescribing Instructions
Patients should take pemigatinib according to the treatment schedule prescribed for their condition.
The U.S. reference-product schedule for qualifying cholangiocarcinoma is 13.5 mg daily for 14 days followed by seven days off treatment.
The U.S. labeled schedule for qualifying FGFR1-rearranged myeloid/lymphoid neoplasms is 13.5 mg daily continuously.
These schedules are different.
Patients should not switch between schedules, increase doses or restart interrupted treatment without professional instructions.
Conclusion
Safety monitoring is an essential part of pemigatinib treatment.
Important concerns include hyperphosphatemia, ocular toxicity, nail and skin reactions, gastrointestinal symptoms and drug interactions.
Patients should attend scheduled examinations, complete recommended blood tests and report new symptoms promptly.
Pemitinib-specific product instructions must be verified independently. All treatment decisions should be made by qualified healthcare professionals.